Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Date:5/5/2009

ally from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the current distressed economic and financial market; the Company's research and development activities; the results of preclinical and clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which will be filed with the SEC on or about May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

                         Poniard Pharmaceuticals, Inc.
                 Condensed Consolidated Statements of Operations
                     (In thousands, except per 
'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Jan. 5, 2011 Although smoking is an expensive habit, ... quit smoking can seem like expensive purchases as well.  The ... try to do it "cold turkey" – the most popular ... to relapse.   The use of store brand ...
... Avaxia Biologics, Inc., a privately-held biotech company developing ... to the gastrointestinal tract, announced today that it ... of inflammatory bowel disease (IBD). Avaxia,s orally administered ... three different animal models and showed superior efficacy ...
Cached Medicine Technology:Resolved to Quit Smoking This Year? 2Resolved to Quit Smoking This Year? 3Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2
(Date:9/1/2014)... Developers of FCPX 3rd Party Products have announced ... Plugin from Pixel Film Studios. , “ProWorld has pushed the ... users now have the ability to create a 3D world ... Pixel Film Studios. “Blurring the line between professional and armature, ... turn a 2D HDRI image or Skybox Texture into a ...
(Date:9/1/2014)... 2014 Psychogenic Non-epileptic Seizures (PNES), also ... disorder that can have devastating effects on those who ... seizures however, they are not produced by electrical anomalies ... It is estimated that the numbers of persons suffering ... sclerosis. , Dr. Lorna Myers, Director of ...
(Date:8/31/2014)... An analysis of 32 studies compiled by ... link between lower levels of Vitamin D and a ... August 2014 issue of American Journal of Public ... Vitamin D found in blood. , Researchers found ... than 9 nanograms/milliliter (ng/mL) were twice as likely to ...
(Date:8/31/2014)... 2014 MedixSafe has become very popular ... and narcotics lockers . Electronic Security Specialists ... for distribution worldwide. “We have now shipped multiple orders ... MedixSafe Sales Manager , MedixSafe is a division of ... network cabling company with over 30 years in the ...
(Date:8/31/2014)... 2014 Just in time for Washington’s Indian ... wild, sustainable Alaska Salmon, award winning chowder and ... Duke's Green Lake location , Sunday, September 28, 2014 from ... several ethnic salmon BBQ culinary delights. Live music will add ... Hawaii, Puerto Rico and Mexico will be featured. “There ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... took place even in prehistoric times. , , FRIDAY, June 13 ... based on the findings of a prehistoric mass grave in ... evidence from 34 skeletons dating back to around 5000 B.C. ... over the need for female companionship. , While adult ...
... June 13 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases,announced ... Chief Executive Officer,will present a Company overview ... Organization 2008 Annual International Convention,being held June ...
... trachomatis, the most ... Calif., June 13 Roche announced today that,its new ... Mark,certification, allowing it to be sold for clinical use ... target approach to help ensure,reliability of test results even ...
... terrorist attacks of September 11, 2001, had lasting psychological ... World Trade Center Health Registry, show that one in ... (PTSD) two to three years after the attacks. The ... three times the usual rate in the years following ...
... for Prevention, Mental,Health and Low-Income Programs, Boosted Quality ... Today a minority of,the U.S. Senate blocked critical ... million Americans who depend on it. The Medicare,Improvements ... improved,Medicare,s prevention, mental health, and low-income programs and,instituted ...
... Synovics,Pharmaceuticals, Inc., (OTC Bulletin Board: SYVC) a ... 2008, it formalized,a strategic partnership with Maneesh Pharmaceuticals, ... ("JV"). The JV between the,companies is intended to ... have access,to assets of Maneesh including personnel, drug ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
Binocular indirect ophthalmic lenses. Median field diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... Volk's super series ... lenses. General retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Standard BIO examinations....
Medicine Products: